Evidence map›Paper›PMID 29843720›Full record

ArticleLipids in health and disease2018

Soluble epoxide hydrolase inhibitors, t-AUCB, downregulated miR-133 in a mouse model of myocardial infarction.

Yajun Gui, Da Li, Jingyuan Chen, Yating Wang, Jiahui Hu, Caixiu Liao, Limin Deng, Qunyan Xiang, Tao Yang, Xiao Du and 2 more

Open access · goldAbstract read
In one paragraph

Article in Lipids in health and disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Therapeutic Value of miRNAs in Coronary Artery Disease.Oxidative medicine and cellular longevity · 2021
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Yajun GuiDepartment of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Da LiDepartment of Geratology, Internal Medicine, the Third Hospital of Changsha, Changsha, Hunan, 410011, China.
Jingyuan ChenDepartment of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Yating WangDepartment of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Jiahui HuDepartment of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Caixiu LiaoDepartment of Geratology, Internal Medicine, the Third Hospital of Changsha, Changsha, Hunan, 410011, China.
Limin DengCenter for Pulmonary Vascular Disease, FuWai Hospital & Cardiovascular Institute Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Qunyan XiangDepartment of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Tao YangDepartment of Cardiology, Internal Medicine, Changsha Central Hospital, Changsha, Hunan, 410011, China.
Xiao DuDepartment of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Shilan ZhangDepartment of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Danyan XuDepartment of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China. xudanyan02@csu.edu.cn.
Second Xiangya Hospital of Central South University · CNCentral South University · CNThird Hospital of Changsha · CNChangsha Central Hospital · CNFu Wai Hospital · CN

Funding

National Natural Science Foundation of China 81372117,81672264the Universities of Central South University 2017zzts227
6 · The paper itself

Abstract

backgroundIt has been demonstrated that soluble epoxide hydrolase inhibitors (sEHIs) are protective against ischemia-induced lethal arrhythmias, but the mechanisms involved are unknown. Previously, we showed that sEHIs might reduce the incidence of ischemic arrhythmias by suppressing microRNA-1 (miR-1) in the myocardium. As miR-1 and miR-133 have the same proarrhythmic effects in the heart, we assumed that the beneficial effects of sEHIs might also relate to the regulation of miR-133.

methodsA mouse model of myocardial infarction (MI) was established by ligating the coronary artery. The sEHI t-AUCB (trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid) was administered daily for 7 days before MI. Myocardial infarct size and cardiac function was assessed at 24 h post-MI. The miRNA expression profiles of sham and MI mice treated with or without t-AUCB were determined by microarray and verified by real-time PCR. The incidence of arrhythmias was assessed by in vivo electrophysiologic studies. The mRNA levels of miR-133, its target genes (KCNQ1 [potassium voltage-gated channel subfamily Q member 1] and KCNH2 [potassium voltage-gated channel subfamily H member 2]), and serum response factor (SRF) were measured by real-time PCR; KCNQ1, KCNH2, and SRF protein levels were assessed by western blotting.

resultsWe demonstrated that the treatment with sEHIs could reduce infarct size, improve cardia function, and prevent the development of cardiac arrhythmias in MI mice. The expression levels of 14 miRNAs differed between the sham and MI groups. t-AUCB treatment altered the expression of eight miRNAs: two were upregulated and six were downregulated. Of these, the muscle-specific miR-133 was downregulated in the ischemic myocardium. In line with this, up-regulation of miR-133 and down-regulation of KCNQ1 and KCNH2 mRNA/protein were observed in ischemic myocaridum, whereas administration of sEHIs produced an opposite effect. In addition, miR-133 overexpression inhibited expression of the target mRNA, whereas t-AUCB reversed the effects. Furthermore, SRF might participate in the negative regulation of miR-133 by t-AUCB.

conclusionsIn MI mice, sEHI t-AUCB can repress miR-133, consequently stimulating KCNQ1 and KCNH2 mRNA and protein expression, suggesting a possible mechanism for its potential therapeutic application in ischemic arrhythmias.

Indexed as

AnimalsArrhythmias, CardiacBenzoatesDisease Models, AnimalDown-RegulationERG1 Potassium ChannelGene Expression RegulationKCNQ1 Potassium ChannelMaleMiceMicroRNAsMyocardial InfarctionMyocardiumRNA, MessengerUrea4-(4-(3-adamantan-1-ylureido)cyclohexyloxy)benzoic acidBenzoatesERG1 Potassium ChannelKCNH2 protein, humanKCNQ1 Potassium ChannelKCNQ1 protein, humanMicroRNAsMirn133 microRNA, mouseRNA, MessengerUreaIschemic arrhythmiaSoluble epoxide hydrolase inhibitors, miR-133

Identifiers

PMID29843720
PMCPMC5975509
OpenAlexW2807513396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.